Pamela Munster, MD
Hematology & Oncology · San Francisco, CANPI 1619997145
Payments from drug & device makers
Across 710 payments — averaging $19,365 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2.9M
- Merck$2.4M
- Amgen$2M
- Corcept Therapeutics$1.9M
- Novartis$1.6M
- AstraZeneca$876K
- plus $2.1M from 23 others
Across 13 payments — averaging $3758.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$47K
- Bristol Myers Squibb$886
- Novartis$686
- Eli Lilly$191
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 156 | $2,901,450 |
| Merck | 98 | $2,351,252 |
| Amgen | 28 | $2,034,140 |
| Corcept Therapeutics | 12 | $1,864,925 |
| Novartis | 21 | $1,617,653 |
| AstraZeneca | 17 | $876,089 |
| AbbVie | 138 | $367,114 |
| Pfizer | 6 | $337,690 |
| Eli Lilly | 9 | $273,990 |
| Clovis Oncology, Inc. | 8 | $244,744 |
| Blueprint Medicines Corporation | 23 | $234,129 |
| Seagen Inc. | 14 | $151,865 |
| Incyte Corporation | 28 | $136,523 |
| Deciphera Pharmaceuticals Inc. | 100 | $108,520 |
| Genentech, Inc. | 18 | $90,443 |
| Sanofi US Services Inc. | 10 | $45,444 |
| Ipsen Bioscience Inc. | 3 | $26,112 |
| Bristol Myers Squibb | 2 | $22,944 |
| Tesaro, Inc. | 1 | $20,982 |
| E.r. Squibb & Sons, L.L.C. | 2 | $20,640 |
| Janssen Global Services, LLC | 1 | $6,500 |
| Sanofi | 4 | $4,604 |
| Athenex Pharmaceutical Division, LLC | 4 | $2,600 |
| Alkermes, Inc. | 1 | $2,600 |
| Organon | 1 | $2,500 |
| Astrazeneca UK Limited | 1 | $2,055 |
| Bayer | 1 | $1,199 |
| Boehringer Ingelheim International GmbH | 1 | $370 |
| Gilead | 2 | $125 |
How this compares
$13,749,201 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in San Francisco
- Alain AlgaziSan Francisco$119.2M
- Collin BlakelySan Francisco$8.8M
- Terence FriedlanderSan Francisco$3.8M
- David BerzLos Angeles$43.3M
- Jonathan GoldmanSanta Monica$35.7M
- Omid HamidSanta Monica$23.7M
- Nicholas McAndrewLos Angeles$22.9M
- Aditya BardiaSanta Monica$22.1M
- Joseph TuscanoSacramento$20.4M
- Zev WainbergSanta Monica$19.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.